10 studies found for:    "microbicide" AND "gel" | Open Studies | HIV
Show Display Options
RSS Create an RSS feed from your search for:
"microbicide" AND "gel" | Open Studies | HIV
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use
Condition: HIV
Interventions: Drug: PC-1005;   Drug: HEC gel
2 Recruiting Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services
Condition: HIV
Intervention: Drug: 1% tenofovir gel
3 Not yet recruiting Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel
Condition: HIV Prevention
Interventions: Drug: Once Daily Application of TFV RG 1% Gel;   Drug: Once Daily Application of TFV RG 1% gel - Rectal;   Drug: Once Daily Application of TFV RG 1% Gel - Vaginal
4 Unknown  An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots
Condition: HIV Infections
Intervention: Drug: HEC placebo gel
5 Recruiting Assessing the Safety of Dapivirine Gel and Film Formulations
Condition: HIV Infections
Interventions: Drug: Dapivirine Vaginal Film;   Drug: Dapivirine Vaginal Gel
6 Not yet recruiting Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women
Condition: HIV Infections
Interventions: Drug: 1% tenofovir gel;   Drug: Placebo gel
7 Recruiting A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04
Condition: HIV
Interventions: Drug: 1% vaginally applied tenofovir gel;   Drug: Tenofovir film- 10mg;   Drug: Tenofovir Film-40 mg
8 Recruiting Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Condition: HIV
Interventions: Drug: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet);   Drug: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel);   Drug: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
9 Recruiting In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products
Condition: HIV Prevention
Interventions: Drug: Tenofovir 1% gel;   Drug: Vaginal product
10 Unknown  Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra
Conditions: Children With Confirmed HIV Infection;   Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose;   Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment
Intervention: Drug: Mycobutin

Indicates status has not been verified in more than two years